Skip to main content

BSI Merges with MBC to Secure Access to Nanoarray Technology and New Academic and Pharma Markets


Diagnostics firm Biosystems International announced this week that it will merge with microarray-maker MicroBioChips.

The merger will give BSI access to MicroBioChips' nanoarray technology and its sales and marketing resources, which are expected to help the company "establish collaborative research and sales [relationships] with university-based proteomics laboratories" and with "pharmaceutical companies, biotechnology companies, and university resource laboratories," Laszlo Takacs, the company's founder and chief scientific officer, told ProteoMonitor.

"This is a very important expectation from our side," he said. MBC has "an experienced marketing and sales force in this domain. They have a name in this field."

Looking ahead, BSI said it hopes to use nanoarray technology being developed at MBC to build point-of-care diagnostic assays, Takacs said.

"Point-of-care device development for multivariate assays using antibodies can be done much more easily with nanotechnology-based arrays," he said. "That's essentially the advantage."

Such a use for MBC's nanoarray technology is still several steps away from a feasibility study, he noted.

In July, BSI closed a $2.7 million private-equity financing round to help it develop a protein biomarker-based lung cancer diagnostic, which it hopes to market sometime in 2011 (07/23/2010).

The company is also working on diagnostics for breast and colon cancer that William Hempel, BSI's director of scientific communication, this week told ProteoMonitor sister publication BioArray News, will "soon enter development" (09/14/2010). It also has tests for obesity and alcohol-induced liver disease that are still in the early research phase.

According to the firms, the partial transfer of MBC's assets to BSI was approved by MBC's shareholders in July. Prior to the merger agreement, BSI pocketed €2.1 million ($2.8 million) in new capital, while MBC nabbed €225,000. Together, the cash infusions "assur[e] the merged firm has sufficient capital for future development."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.